REG - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

05/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241205:nRSE8797Oa&default-theme=true

RNS Number : 8797O  Physiomics PLC  05 December 2024

5 December 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

Contract Award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is delighted to announce it has been awarded a new
contract with a long-standing, globally recognised pharmaceutical client. The
project, valued at £157k, will leverage Physiomics' expertise in
Pharmacokinetic-Pharmacodynamic ("PKPD") modelling to inform critical
pre-clinical and clinical dosing and scheduling decisions for a novel cancer
treatment combination. Delivery of the project is expected to complete within
the next 12 months.

This new project represents a significant expansion of the ongoing
collaboration between Physiomics and its client, marking the first
incorporation of an Antibody-Drug Conjugate ("ADC") into the company's Virtual
Tumour ("VT") modelling platform. ADCs are a rapidly advancing class of
targeted therapies in oncology, offering enhanced precision by enabling tumour
specific delivery of potent cytotoxic payloads. This project positions
Physiomics at the forefront of this exciting field of drug development.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"This new contract demonstrates the strength and longevity of our
collaboration with one of the world's leading pharmaceutical companies and
reflects their trust in our modelling expertise to support the development of
advanced therapies. We are particularly excited to expand our Virtual Tumour
platform to include ADCs - a hot topic in cancer treatment right now. We look
forward to starting work on this project and continue to demonstrate our
expertise across a diverse range of therapeutic approaches."

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEAFALEDLLFAA